Tesamorelin in plain English — the GHRH analog FDA-approved for visceral fat
6 min read · Uplevel editorial
You can be technically lean and still have a problem with visceral fat. The number on the scale cooperates. The waist measurement doesn't. You eat carefully, you exercise — the subcutaneous fat over your hips and thighs shifts over years of work, but the deep abdominal fat, the kind that sits around your organs and shows up on imaging as a dense metabolically active mass, seems almost indifferent to everything you do. Your provider's answer, if you're lucky, is "keep up the good work." If you're less lucky, it's a referral to a nutritionist who tells you to eat more fiber.
This kind of fat is not inert padding. Visceral adipose tissue is metabolically active in ways that subcutaneous fat largely isn't. It secretes inflammatory cytokines — including TNF-alpha and IL-6 — at higher rates than fat elsewhere in the body. It's more directly connected to hepatic circulation, meaning the liver is downstream of its secretory activity. Elevated visceral adipose is associated with insulin resistance, dyslipidemia, increased cardiovascular risk, and non-alcoholic fatty liver disease in ways that total body fat or BMI don't fully capture. Two people with identical BMI can have dramatically different visceral fat burdens — and dramatically different metabolic risk profiles.
Tesamorelin is a compound that was developed specifically around visceral fat, though the population it was developed for had a specific reason for accumulating it. The story begins with antiretroviral therapy and HIV lipodystrophy.
HIV-associated lipodystrophy is a body composition disorder that emerged as antiretroviral regimens became effective enough to extend life significantly. Patients on older classes of antiretrovirals — particularly protease inhibitors and thymidine analogue nucleoside reverse transcriptase inhibitors — developed a characteristic pattern of fat redistribution: peripheral fat loss combined with marked central fat accumulation, particularly visceral. The mechanisms involve direct mitochondrial toxicity from certain ARV drugs, disruption of adipocyte differentiation, and secondary effects on GH secretion. The result is a pronounced visceral adipose accumulation that carries real cardiovascular and metabolic consequences and, separately, significant effects on quality of life and physical appearance.
Tesamorelin was studied in this population and received FDA approval in 2010 under the brand name Egrifta, specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. That indication is narrow, clearly defined, and supported by robust clinical data. Everything beyond that is off-label.
The mechanism is what makes tesamorelin different from direct interventions. It doesn't act on fat cells directly. It works upstream, at the pituitary.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone — GHRH — chemically stabilized by the addition of a trans-3-hexenoic acid group that protects it from enzymatic degradation and extends its plasma half-life substantially beyond native GHRH. Once injected subcutaneously, it travels to the anterior pituitary and binds to the GHRH receptor on somatotroph cells, the same receptor that endogenous hypothalamic GHRH binds to. The pituitary responds by releasing growth hormone in pulses — not a flat elevation, but an amplification of the existing pulsatile pattern, preserving the biological character of physiological GH secretion.
That increased GH activity drives several downstream effects, but the one most relevant to visceral fat is lipolysis. GH is a potent lipolytic hormone. It activates hormone-sensitive lipase in adipose tissue, promoting the breakdown of triglycerides into free fatty acids. The reason this effect is preferentially expressed in visceral adipose — rather than fat more broadly — relates to receptor density and biology: visceral adipocytes have higher GH receptor expression than subcutaneous adipocytes, and they're more sensitive to lipolytic signaling. The result is relatively selective mobilization of visceral fat under GH stimulation.
GH also acts on the liver to stimulate IGF-1 production, and IGF-1 rises modestly with tesamorelin use — typically within normal physiological range, rather than the supraphysiological elevations associated with exogenous HGH. The elevation in IGF-1 is important as a biomarker for GH response, and it also carries some of the secondary anabolic effects attributed to GH — protein synthesis support, glucose handling modulation — though these are not the primary focus of tesamorelin's studied applications.
In the clinical trials that supported FDA approval, daily subcutaneous tesamorelin at 2 mg produced statistically significant reductions in visceral adipose tissue volume — measured by CT scan — at 26 and 52 weeks in HIV-lipodystrophy patients. The effect was meaningful: roughly 15-20% reduction in visceral fat in the treated groups, compared to no significant change with placebo. Triglycerides improved. The trunk-to-limb fat ratio shifted favorably. When treatment was discontinued, visceral fat tended to return, indicating that the effect depends on continued treatment rather than representing a permanent change.
The adverse effect profile from clinical trials is worth understanding honestly. Injection site reactions — redness, swelling, itching — are common and represent the most frequent reason for discontinuation. Joint discomfort and myalgia appear at rates meaningfully above placebo. Peripheral edema, driven by the fluid-retaining effects of elevated GH, is documented. Glucose handling requires attention: GH opposes insulin action, and tesamorelin produces modest elevations in fasting glucose and HbA1c in some patients. In people already at the margins of glucose tolerance, this is clinically relevant. Baseline and ongoing glucose monitoring is appropriate. The compound is contraindicated in active malignancy and disrupts the HPG axis in ways that require consideration in people with known hormone-sensitive conditions.
One pharmacokinetic detail matters practically: tesamorelin has a plasma half-life of roughly twenty-six minutes after subcutaneous injection, but its stimulatory effect on pituitary GH release extends over a period of hours. Daily injection is the standard dosing schedule in clinical practice, consistent with the studied protocol. The injection is subcutaneous, typically into the abdomen, with rotation of sites to minimize localized reactions.
What tesamorelin accomplishes, when it works, is a GH-mediated reduction in visceral adipose that operates through the body's own pituitary machinery rather than through exogenous hormone delivery. The pituitary's feedback mechanisms remain operative — somatostatin still rises in response to elevated GH, preventing the runaway GH elevation that characterizes exogenous HGH use. This is the structural reason that tesamorelin's metabolic side-effect profile is substantially cleaner than direct GH injection, even while producing meaningful visceral fat reduction.
The visceral fat problem, for many people, is refractory to standard interventions in a way that feels both unfair and medically invisible. You can lose twenty pounds and the organ fat barely moves. Tesamorelin doesn't rewrite that biology, but it accesses a lever — the GH axis and its preferential effect on visceral adipose — that diet and exercise largely don't reach. The clinical data, in the population it was studied in, makes that meaningful. Whether and how that applies to populations with visceral fat accumulation from other causes is a different and more complicated question — one that requires a provider who has reviewed the evidence and can situate it in the context of a full clinical picture.
Frequently asked